Global Cancer Technology

Global Cancer Technology

Early Stage

GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.

GCT’s lead cancer technology is its remote-controlled cancer drug delivery platform.


Raised this Round: Raised: $24,400

Total Commitments ($USD)


Dalmore Group

Start Date


Close Date

Not Provided

Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Common

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share


Year Founded



Healthcare & Pharmaceuticals

Tech Sector



San Diego, California

Global Cancer Technology is raising funds on Dalmore Group through Reg A+ crowdfunding. The company has acquired multiple patented technologies currently being tested as novel treatments for deadly diseases. The technology is presently focused on detecting and treating brain cancer and includes scintillating nanoparticles, cancer biomarkers, and cancer inhibitors. Global Cancer Technology is working with world-renowned scientists of the Barrow Neurological Institute, Baylor Scott & White Hospital, and the University of California San Diego. John P. Clark founded Global Cancer Technology in May 2017. The current crowdfunding campaign has no minimum target and a maximum target of $7,000,000. The campaign proceeds will be used for new product development, working capital, and general corporate purposes.

Balance Sheet

Cash and Cash Equivalents


Property, Plant and Equipment (PP&E)


Total Assets


Accounts Payable & Accrued Liabilities


Total Liabilities


Total Stockholders' Equity


Total Liabilities and Equity


Statement of Comprehensive Income Information

Depreciation and Amortization


Net Income


Earnings Per Share - Basic


Earnings Per Share - Diluted


Auditor: Ankit Consulting Inc.
Financials as of: 09/07/2020
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Global Cancer Technology 04/28/2022 Netcapital $26,682,636 $0 Equity - Common Not Funded RegCF
Global Cancer Technology 09/07/2021 Dalmore Group - $24,400 Equity - Common Funded RegA+
Global Cancer Technology 02/24/2020 Netcapital $11,571,400 $107,000 Equity - Common Funded RegCF
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Global Cancer Technology on Dalmore Group 2021
Platform: Dalmore Group
Security Type: Equity - Common
Price per Share: $2.00

Follow company

Follow Global Cancer Technology on Dalmore Group 2021

Buy Global Cancer Technology's Deal Report

Warning: according to the close date for this deal, Global Cancer Technology may no longer be accepting investments.

Global Cancer Technology Deal Report

Get KingsCrowd’s comprehensive report on Global Cancer Technology including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Global Cancer Technology is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Global Cancer Technology deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge